Skip to main content
. 2022 Dec 4;197(3):503–513. doi: 10.1007/s10549-022-06775-1

Table 2.

AEs of interest to pertuzumab therapy in the safety population

Pertuzumab plus trastuzumab plus docetaxel (n = 122) Placebo plus trastuzumab plus docetaxel (n = 120)
Diarrhea 56 (45.9) 28 (23.3)
 Grade ≥ 3 5 (4.1) 2 (1.7)
Rash 36 (29.5) 22 (18.3)
 Grade ≥ 3 2 (1.6) 3 (2.5)
Leukopenia 96 (78.7) 89 (74.2)
 Grade ≥ 3 74 (60.7) 73 (60.8)
Leukopenia infection 6 (4.9) 3 (2.5)
 Grade ≥ 3 1 (0.8) 0
Febrile neutropenia 5 (4.1) 5 (4.2)
 Grade ≥ 3 5 (4.1) 5 (4.2)
Febrile neutropenia infection 0 0
 Grade ≥ 3 0 0
Anaphylaxis and hypersensitivity 2 (1.6) 1 (0.8)
 Grade ≥ 3 0 1 (0.8)
Infusion-related reactions 41 (33.6) 29 (24.2)
 Grade ≥ 3 4 (3.3) 3 (2.5)
Mucositis 32 (26.2) 12 (10.0)
 Grade ≥ 3 4 (3.3) 0
Interstitial lung disease 2 (1.6) 4 (3.3)
 Grade ≥ 3 0 0

Data are number of patients, n (%)

AEs to monitor, i.e., AEs that the health authorities requested to be monitored closely (usually potential risks or missing information)

AE adverse event